MRVI vs. CTLT, ROIV, ELAN, ASND, LEGN, CERE, VKTX, ITCI, JAZZ, and BPMC
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Catalent (NYSE:CTLT) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.
Maravai LifeSciences has lower revenue, but higher earnings than Catalent. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.
Catalent presently has a consensus target price of $53.14, suggesting a potential downside of 2.48%. Maravai LifeSciences has a consensus target price of $11.44, suggesting a potential upside of 5.77%. Given Catalent's stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Catalent.
In the previous week, Maravai LifeSciences had 1 more articles in the media than Catalent. MarketBeat recorded 4 mentions for Maravai LifeSciences and 3 mentions for Catalent. Catalent's average media sentiment score of 1.51 beat Maravai LifeSciences' score of 1.39 indicating that Maravai LifeSciences is being referred to more favorably in the news media.
Catalent has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
Catalent received 582 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 67.44% of users gave Maravai LifeSciences an outperform vote while only 59.20% of users gave Catalent an outperform vote.
50.3% of Maravai LifeSciences shares are owned by institutional investors. 0.3% of Catalent shares are owned by insiders. Comparatively, 0.6% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Catalent has a net margin of -26.61% compared to Catalent's net margin of -47.81%. Maravai LifeSciences' return on equity of -2.73% beat Catalent's return on equity.
Summary
Maravai LifeSciences beats Catalent on 11 of the 18 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
